(Reuters) - Net profit fell to $6.1 million, or 5 cents a share, from $11 million, or 10 cents a share, a year ago. Analysts had on average expected earnings of 36 cents a share, according to Reuters Estimates.
Revenue rose a less-than-expected 5 percent to $278.1 million, with sales of insomnia drug Lunesta growing just 3 percent to $143.0 million as it struggled to fight off competition from a generic version of rival Ambien.
Read more at Reuters.com Mergers News
Revenue rose a less-than-expected 5 percent to $278.1 million, with sales of insomnia drug Lunesta growing just 3 percent to $143.0 million as it struggled to fight off competition from a generic version of rival Ambien.
Read more at Reuters.com Mergers News
No comments:
Post a Comment